Get the Stockscreener App
14.81
2.31%
-0.35
After Hours:
15.46
0.65
+4.39%
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian
Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
Arcutis Issues 27,000 RSUs: What This Employee Compensation Move Signals - StockTitan
Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World
Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise
Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com India
Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock By Investing.com - Investing.com UK
Seborrhea Clinical and Non-Clinical Studies, Key Companies, - openPR
Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com
Arcutis Biotherapeutics Shines in Earnings Call - TipRanks
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $15.00 - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $21.00 Price Target at Mizuho - MarketBeat
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - The Manila Times
Can Arcutis' New ZORYVE Clinical Data Transform Treatment Options for Dermatology Patients? - StockTitan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $21.00 - Defense World
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial - ACCESS Newswire
FDA accepts sNDA for Arcutis’ Zoryve in young children with eczema - The Pharma Letter
Arcutis: ZORYVE Net Product Revenue Growth Isn't Only Opportunity On Deck (ARQT) - Seeking Alpha
Strong Sales Growth and Financial Stability Drive Buy Rating for Arcutis Biotherapeutics - TipRanks
Mizuho lifts Arcutis stock price target to $21 from $20 By Investing.com - Investing.com Australia
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children - Managed Healthcare Executive
Arcutis rises as lead product undergoes FDA review for label expansion - MSN
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations - Seeking Alpha
Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion - TipRanks
Arcutis Biotherapeutics rises on strong sales of skin disease drug - TradingView
Arcutis stock rises on FDA review for Zoryve (ARQT:NASDAQ) - Seeking Alpha
FDA sets review date for new eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream - Marketscreener.com
FDA sets review date for new eczema cream for young children - Investing.com India
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):